Genetic Susceptibility and Treatment Personalization in Acute Lymphoblastic Leukemia: A Comprehensive Review of Genetic Susceptibility and Targeted Therapies

Abstract

Acute lymphoblastic leukemia (ALL) in children is a complicated and heterogeneous disease impacted by various genetic susceptibility factors. The significance of genetic testing in pediatric ALL diagnosis and management, the role of minimal residual disease (MRD) monitoring, and ethical issues and problems in pediatric genetic testing are discussed in this narrative review. It also looks ahead to the future of genetic susceptibility research, focusing on data integration, artificial intelligence-driven insights, and the possible finding of novel treatment targets. We hope to provide a complete view of the current status and hopeful future of precision medicine in pediatric oncology as we traverse these numerous facets of pediatric ALL. Pediatric ALL is a significant problem in the world of pediatric cancer, requiring a detailed understanding of its genetic foundations and the importance of genetic testing. This narrative review investigates the complex world of pediatric ALL, shedding light on the intricate web of genetic susceptibility factors that influence the progression and treatment results. While we investigate the importance of genetic testing, the critical function of MRD monitoring, and the ethical concerns inherent in pediatric genetic testing, we also look forward to the potential horizons of genetic susceptibility research.

Keywords

• cytokine receptor-like factor
• lymphoblastic leukemia
• minimal residual disease